Education
About Us
Working with TipRanks
Follow Us
XT - ETF AI Analysis
Top Page
iShares Exponential Technologies ETF (XT)
Rating:69Neutral
Price Target:―
Positive Factors
Large Asset Base
The fund manages a sizable pool of assets, which can support liquidity and trading efficiency for investors.
Balanced Tech and Health Care Exposure
A mix of technology and health care holdings spreads growth opportunities across two major innovation-driven sectors.
Resilient Top Holdings
Several of the largest positions, such as Texas Instruments, Analog Devices, Johnson & Johnson, Alphabet, and Eli Lilly, have shown steady to strong performance, helping support the ETF’s overall results.
Negative Factors
Recent Short-Term Weakness
The ETF has experienced weak performance over the last three months, which may signal near-term volatility or pressure on its strategy.
Mixed Performance Among Top Stocks
Some major holdings like Nvidia, Tesla, Microsoft, and AbbVie have been lagging this year, which can drag on the fund’s returns.
Above-Average Expense Ratio
The fund’s expense ratio is higher than many broad market index ETFs, meaning more of the return is used to cover fees.
XT vs. SPDR S&P 500 ETF (SPY)
AUM3.63B
RegionGlobal
Expense Ratio0.46%
Beta1.10
IssueriShares
Inception DateMar 19, 2015
Dividend Yield7.68%
Asset ClassEquity
Index TrackedMorningstar Exponential Technologies Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume185,373
30 Day Avg. Volume112,999
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
83.88Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering179
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XT Summary
The iShares Exponential Technologies ETF (XT) tracks the Morningstar Exponential Technologies Index, focusing on companies using cutting-edge tech like artificial intelligence, robotics, and advanced healthcare tools. It holds many U.S. stocks and spreads investments across technology, health care, and other sectors. Well-known holdings include Nvidia, Microsoft, Amazon, and Eli Lilly. Someone might invest in XT to seek long-term growth from innovative companies while still getting diversification across many industries. A key risk is that it is heavily exposed to fast-changing technology trends, so its price can rise and fall more sharply than the overall market.
How much will it cost me?The iShares Exponential Technologies ETF (XT) has an expense ratio of 0.46%, meaning you’ll pay $4.60 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it is actively managed to focus on innovative and emerging technologies, which require more research and specialized expertise.
What would affect this ETF?The iShares Exponential Technologies ETF (XT) could benefit from continued advancements in technology, such as artificial intelligence and robotics, which are driving innovation across industries globally. However, it may face challenges from rising interest rates, which can impact growth-focused companies, and potential regulatory changes affecting key sectors like healthcare and technology. Its global exposure and diversified holdings provide resilience, but economic slowdowns or geopolitical tensions could negatively affect its performance.
XT Top 10 Holdings
XT is riding a wave of innovation with a clear tilt toward U.S. tech and healthcare leaders. On the tech side, Texas Instruments and Analog Devices have been climbing steadily, while Alphabet has added extra spark with a strong rebound. Eli Lilly and Johnson & Johnson are the healthcare heavyweights quietly pulling their weight. Offsetting that strength, Tesla is dragging the fund, and Microsoft and AbbVie have been losing steam lately. Overall, the ETF is concentrated in big-name chips, software, and drugmakers within a global, but U.S.-heavy, portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Texas Instruments | 4.20% | $153.69M | $201.21B | 21.33% | 78 Outperform | |
| Eli Lilly & Co | 4.04% | $147.86M | $1.00T | 20.23% | 72 Outperform | |
| Nvidia | 3.95% | $144.60M | $4.51T | 42.28% | 76 Outperform | |
| Tesla | 3.66% | $134.04M | $1.54T | 18.99% | 73 Outperform | |
| Analog Devices | 3.43% | $125.62M | $156.58B | 57.65% | 78 Outperform | |
| Microsoft | 3.25% | $118.93M | $2.98T | 0.33% | 79 Outperform | |
| Johnson & Johnson | 3.24% | $118.73M | $578.21B | 54.72% | 78 Outperform | |
| Amazon | 2.71% | $99.09M | $2.25T | -10.47% | 71 Outperform | |
| Alphabet Class A | 2.48% | $91.02M | $3.91T | 73.93% | 85 Outperform | |
| AbbVie | 2.21% | $81.03M | $394.89B | 17.30% | 66 Neutral |
XT Technical Analysis
Positive
―
Price Trends
70.89
Positive
69.43
Positive
64.63
Positive
Market Momentum
0.21
Positive
53.70
Neutral
37.22
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 72.12, equal to the 50-day MA of 70.89, and equal to the 200-day MA of 64.63, indicating a bullish trend. The MACD of 0.21 indicates Positive momentum. The RSI at 53.70 is Neutral, neither overbought nor oversold. The STOCH value of 37.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XT.
XT Peer Comparison
Comparison Results
Performance Comparison
XT
iShares Exponential Technologies ETF
72.23
14.08
24.21%
CIBR
First Trust NASDAQ Cybersecurity ETF
―
―
―
IGF
iShares Global Infrastructure ETF
―
―
―
BAI
iShares A.I. Innovation and Tech Active ETF
―
―
―
GUNR
FlexShares Morningstar Global Upstream Natural Resources Index Fund
―
―
―
GRID
First Trust Nasdaq Clean Edge Smart GRID Infrastructure Index
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents